Can hydroxyzine be used short‑term for insomnia in an adult patient who has no contraindications such as severe hepatic impairment, narrow‑angle glaucoma, urinary retention, hypersensitivity, pregnancy, or nursing?

Hydroxyzine for Insomnia: Not Recommended as First-Line Treatment

Hydroxyzine should not be used as a first-line treatment for insomnia in adults, even for short-term use, due to lack of demonstrated efficacy and safety concerns identified in major clinical guidelines. 1

Guideline-Based Recommendations

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline explicitly states that over-the-counter antihistamine sleeping aids (which includes hydroxyzine, a first-generation H1 antagonist) are not recommended due to lack of demonstrated efficacy as well as safety concerns 1. While the AASM noted "preliminary but conflicting evidence" for first-generation H1 antagonists for short-term use, this falls far short of a recommendation for clinical use.

Preferred Treatment Algorithm:

1. First-line: Cognitive Behavioral Therapy for Insomnia (CBT-I) - This is the standard of care and should be offered to all patients with chronic insomnia 1

2. Second-line pharmacotherapy (if CBT-I fails or is unavailable):

   • Eszopiclone, zolpidem, or suvorexant (low-to-moderate strength evidence for short-term efficacy) 2
   • Short/intermediate-acting benzodiazepine receptor agonists or ramelteon 1

3. Hydroxyzine is not included in evidence-based treatment algorithms 1

Evidence Quality and Safety Concerns

The most recent systematic review (2023) examining hydroxyzine specifically for insomnia found only 5 small studies with 207 total patients, demonstrating "mixed efficacy" in sleep measures 3. Critically, 4 of these 5 studies did not even report safety outcomes 3. This represents extremely weak evidence compared to FDA-approved hypnotics.

Key Safety Issues:

• Anticholinergic effects: Dry mouth, cognitive impairment, falls risk (particularly concerning in older adults)
• QT prolongation: Hydroxyzine is contraindicated in patients with prolonged QT interval 4
• Pregnancy category concerns: Contraindicated in early pregnancy due to fetal abnormalities in animal studies 4
• Lack of long-term safety data for insomnia indication

Clinical Context

While hydroxyzine may have preliminary evidence suggesting possible short-term benefit 3, the American College of Physicians (2016) found insufficient evidence for most widely-used treatments including sedating antihistamines 2. The observational data showing hypnotics are associated with increased risk for dementia, fractures, and major injury 2 raises particular concern for antihistamines with anticholinergic properties in vulnerable populations.

Common Pitfalls to Avoid:

• Do not prescribe hydroxyzine simply because it's "non-addictive" - lack of dependence potential does not equal efficacy or safety
• Do not use in older adults - anticholinergic burden increases fall risk and cognitive impairment
• Screen for QT prolongation risk factors before any consideration of use 4
• Avoid in patients taking other QT-prolonging medications

When Hydroxyzine Might Be Considered (Cautiously):

The 2023 systematic review suggests hydroxyzine "could be considered as a short-term treatment option for adults with insomnia for whom previous therapy was ineffective, not tolerated, or contraindicated" 3. This positions it as a last-resort option only, after:

• CBT-I has failed or is unavailable
• FDA-approved hypnotics have failed, are contraindicated, or not tolerated
• Patient has no contraindications (QT prolongation, pregnancy, severe hepatic impairment, narrow-angle glaucoma, urinary retention) 4

If used, limit to 25-50 mg at bedtime for the shortest duration possible (based on study dosing) 3, with explicit patient counseling about limited evidence and anticholinergic risks.